Drugs / Anthrax Immune Globulin Intravenous
Anthrax Immune Globulin Intravenous
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00845650 | Feb 2009 → Oct 2010 | anthrax infection | Emergent BioSolutions | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anthrax Immune Globulin Intravenous | “Anthrax Immune Globulin Intravenous (AIGIV)” NCT00845650 ↗ |
| Known as | AIGIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00845650 ↗ |
| Known as | Anthrivig | “Anthrivig (human anthrax immunoglobulin), also known as AIGIV, derived from plasma of humans immunized with BioThrax (anthrax vaccine adsorbed), is under development for the...” PMID 23979731 ↗ Aug 2013 |
| Known as | human anthrax immunoglobulin | “Anthrivig (human anthrax immunoglobulin), also known as AIGIV, derived from plasma of humans immunized with BioThrax (anthrax vaccine adsorbed), is under development for the...” PMID 23979731 ↗ Aug 2013 |
| Modality | Protein / enzyme biologic | “Anthrivig (human anthrax immunoglobulin), also known as AIGIV, derived from plasma of humans immunized with BioThrax (anthrax vaccine adsorbed), is under development for the...” PMID 23979731 ↗ Aug 2013 |
| Route | Intravenous | “AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.” NCT00845650 ↗ |